EDAP TMS announced that the French Ministry of Health has awarded national reimbursement for the High Intensity Focused Ultrasound (HIFU) procedure for the treatment of prostate cancer in France. This significant regulatory milestone allows for the Focal One Robotic HIFU procedure to be covered under France’s national universal health system.
This reimbursement approval is expected to significantly increase patient access to Focal One Robotic HIFU across France. It provides a clear pathway for broader adoption and utilization of the technology in a major European market.
The decision by the French Ministry of Health validates the clinical value of HIFU for prostate cancer treatment. This development is anticipated to drive increased procedure volumes and revenue for EDAP's core HIFU business in the region.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.